Hypnosedative access and risk of harm (original) (raw)

PubMed, 2011

Abstract

Aim: To review PHARMAC's decision, effective 1 September 2010, to remove the 1-month restriction on funded prescription of hypnotics and anxiolytics. Method: We consider the evidence for an association between access to these medicines and risk of harm. Results: Prescription volumes and reported harms have both increased over the last decade in New Zealand; available studies and clinical experience suggest a causal link. Preliminary data collected since PHARMAC's funding change suggest an exacerbation of the problem. Conclusion: The decision to relax funding restrictions on hypnosedatives is expected to increase drug-related harms in a sub-population of users. Improved pharmacovigilance could inform policy regarding these agents.

Mark A Huthwaite hasn't uploaded this paper.

Let Mark know you want this paper to be uploaded.

Ask for this paper to be uploaded.